CD5 CAR T Cells therapy(Beijing GoBroad Hospital)

N/A

Report date: 2024/07/06 20:00:06

Base Information

Drug NameCD5 CAR T Cells therapy(Beijing GoBroad Hospital)
Drug Alias NameAutologous CD5 CAR T-cells therapy(Beijing GoBroad Hospital)
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > PMBC-derived
Mechanisms of ActionT-cell surface glycoprotein CD5 modulatorsT lymphocyte replacements
TargetsT-cell surface glycoprotein CD5
Therapy Area/IndicationsLymphoma, T-Cell, PeripheralLymphoma, T-Cell, CutaneousLymphoma, T-Cell +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing GoBroad Hospital
China Registration ClassN/A

Develop Information

Active CompaniesBeijing GoBroad Hospital
Inactive CompaniesN/A
Active IndicationsLymphoma, T-Cell, PeripheralLymphoma, T-Cell, CutaneousLymphoma, T-Cell +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A